Characterized by high incidence and long treatment durations, the breast cancer market represents a great commercial opportunity for drug developers. CDK4/6 inhibitors (Pfizer’s Ibrance, Novartis Kisqali and Eli Lilly’s Verzenio) are creating new dynamics in the metastatic HR+/HER2– treatment practice. In HER2+ breast cancer, emerging HER2-targeting drugs currently in development are forecasted to enter the market, while current HER2-targeting agents see their sales changing as a result of competition, label expansions, biosimilars entry and new trials leading to changes in treatment guidelines. Furthermore, the approval of AstraZeneca’s Lynparza and anticipated future entry of other PARP inhibitors and immune checkpoint inhibitors will provide more diverse treatment options, especially for triple-negative breast cancer.
- What is the size of the drug-treatable breast cancer population, and how will drug-treatment rates change over time?
- What is the expected market impact of recent drug approvals, such as AZ’s Lynparza, or label extensions like Roche/Genentech’s Perjeta in the HER2 adjuvant setting or Eli Lilly’s Verzenio in HR first-line metastatic setting?
- What are the most promising agents in the pipeline, and how will they shape the future of the breast cancer market?
- What are the drivers and constraints in the breast cancer market, and how will the market evolve over the forecast period?
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.